Latest news

Adalvo is well positioned for Day-1 launches of their generic Tafamidis 61mg soft gel capsules, supported by strong development and IP strategy. Based on the reference brand Vyndamax, Tafamidis is...

Adalvo has commenced pivotal bioequivalence (BE) studies for generic Binimetinib film coated tablets. It’s a significant milestone in bringing an affordable version of this important oncology therapy to patients in...

Adalvo, one of Europe's leading B2B pharmaceutical companies, today announced the appointment of Joan Fusté and Nick Kelly to senior executive roles, effective 1 January 2025. The appointments reflect Adalvo's...

Adalvo is proud to announce the first-to-market launch of generic Brivaracetam film-coated tablets in Croatia, in partnership with one of Europe’s leading generic pharmaceutical companies.  This milestone marks the first...

Adalvo, a leading global pharmaceutical company specialising in the development and commercialisation of complex generics, 505(b)(2), peptides and GLP-1s, today announced an exclusive global development, licence and supply collaboration for...

Adalvo, in partnership with STADA, announces the commercial launch of generic Ivermectin 10mg/g (1%) cream in Germany. It is believed to be the first generic alternative to Soolantra (Galderma) available to patients in Europe. Ivermectin cream...

Adalvo has initiated pilot bioequivalence (BE) studies for its generic Letermovir tablets — a significant milestone in bringing a generic version of this complex, first-in-class antiviral to market. Filings are...

Adalvo has commenced pivotal bioequivalence (BE) studies for its generic Linagliptin and Metformin fixed-dose combination (FDC) tablet.   Coming soon after the company received DCP approval and marketing authorization for its...

Adalvo has confirmed positive results from its bioequivalence (BE) study for its non-infringing difficult-to-develop generic Apalutamide tablets, conducted under both fasting and fed conditions. The study results confirm bioequivalence with...

Adalvo today announced the successful pan-European launch of Nintedanib Soft Gel Capsules, delivered simultaneously across its European partners.  Through operational excellence, Adalvo ensured every element -dossiers, supply chains, and commercial...

Adalvo today announced the signing of a distribution partnership that will bring one of its most technically differentiated oncology assets to patients across the United States and Canada. The agreement...

Adalvo is delighted to announce that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution will be available in the U.S. through our commercial partner, Azurity Pharmaceuticals. Arynta offers a ready-to-use oral liquid option...

Adalvo continues to progress its Ambrisentan + Tadalafil film-coated tablets towards MA approval in Q1 2027. This first-of-its-kind fixed-dose combination (FDC) therapy is indicated to treat Pulmonary Arterial Hypertension (PAH)...

Adalvo's Apalutamide development continues to progress, with the regulatory dossier targeted for completion in Q4 2026. This supports a well-prepared Day-1 submission in Europe following data exclusivity, and early market...

With the pivotal bioequivalence (BE) study successfully completed, Adalvo is set for DCP submission of Lenvatinib Oral Liquid (OL) in April 2026.   Approximately 60% of patients diagnosed with thyroid cancer...

Adalvo has received marketing authorisation via the DCP for its generic Afatinib film-coated tablets in Europe. The approval covers all strengths: 20, 30, 40 and 50 mg.  Afatinib is indicated...

Bioequivalence studies for generic Avatrombopag are now underway, marking a significant development milestone in Adalvo's programme. The company expects to have a global regulatory dossier ready to file in 2026,...

Adalvo is commencing studies for its generic Letermovir tablets. It’s a significant milestone in bringing a generic version of this complex, first-in-class antiviral to market. Letermovir is indicated for the...